Abstract
The incidence of hypertension in young women is likely to increase in the near future because of the rising rates of the metabolic syndrome, obesity and dyslipidaemia worldwide. Consequently, more women will be on antihypertensive agents, which have the potential for teratogenicity. It is also likely that the increasing number of young women with essential hypertension who become pregnant will develop pregnancy-specific disorders such as pre-eclampsia. Health professionals should be aware of the effects of hypertension in women during the childbearing years, as well as the impact of pre-eclampsia on cardiovascular disease in later life. Pre-conception counselling skills, and knowledge on the use of antihypertensives and the changes that occur during pregnancy should be added to the clinical armamentarium of all health professionals.

Keywords: pregnancy hypertension, childbearing years, antihypertensive medication

Submitted 27/11/09, accepted 31/8/10
Cardiovasc J Afr 2011; 22: 330–334 www.cvja.co.za
DOI: 10.5830/CVJA-2010-074

Hypertensive disorders are the commonest medical complications occurring in pregnancy. They occur in approximately 6–8% of all pregnancies in the USA and cover a spectrum of disorders, such as chronic hypertension, gestational hypertension and pre-eclampsia/eclampsia syndrome.1 In South Africa, rates of hypertensive disorders in pregnancy are higher. A community-based study found a 12% incidence of hypertensive disorders in pregnancy in KwaZulu-Natal,2 while a tertiary facility-based study reported a rate of prevalence of 18%.3

Of recent concern is the increasing prevalence worldwide of obesity and the metabolic syndrome. Pregnant women who develop pre-eclampsia de novo share many of the risk features of the metabolic syndrome, namely, dyslipidaemia, obesity and insulin insensitivity. Therefore, increasing numbers of women could develop hypertension in their childbearing years and during pregnancy.

An increase in the numbers of young women presenting with hypertension would create challenges for general medical practitioners, obstetricians and specialist physicians. Firstly, significant hypertension requires investigation for an underlying cause. Secondly, the selection of antihypertensive agents for the treatment of essential hypertension in women of childbearing age poses challenges, as most antihypertensive medications are potentially teratogenic. Thirdly, several well-defined clinical hypertensive conditions, such as pre-eclampsia, are associated with high rates of maternal and neonatal morbidity and mortality. Lastly, hypertensive pregnancy disorders were traditionally not considered to have any long-term deleterious effects on cardiovascular health. However, recent studies have shown that pregnancy-specific hypertension is a risk factor for cardiovascular health later in life.4,5

Intensive counselling on the long-term impact of hypertensive disorders in pregnancy, the potential teratogenic effects of antihypertensive agents, appropriate diagnosis of pregnancy-specific hypertensive conditions and timely interventions therefore require an interdisciplinary approach if complications arising from these conditions are to be minimised.

Treatment of essential hypertension in women of childbearing age
Although the Joint National Committee (JNC7) definition of hypertension and the treatment goals do not vary according to age and gender, the use of antihypertensive drugs in women of childbearing age and during pregnancy should be carefully considered in respect of their teratogenic potential.6 It is well established that angiotensin converting enzymes and receptor blockers have similar foetal effects in that they are associated with foetal renal agenesis, especially if used in the first trimester. However, several other antihypertensive agents seem to carry minimal teratogenic risks to the foetus (Table 1).

Women of childbearing age with class I hypertension usually do not require antihypertensive medications.7 Successful lifestyle modifications and exercise in this group have been reported to demonstrate better blood pressure control.7,8 Furthermore, essential hypertension is independently associated with pre-eclampsia, and antihypertensive therapy in this group does not prevent the development of pre-eclampsia/eclampsia.

Normal haemodynamic changes in pregnancy
Physiological changes in pregnancy may mimic signs of early congestive cardiac failure, and all health professionals should be aware of this. Briefly, changes in the cardiovascular system begin early in pregnancy, reaching a maximum at 28 weeks’ gestation. Within the first 12 weeks of pregnancy, the total intravascular
plasma volume increases by 30–40%. Red blood cell mass increases by approximately 20%, but with the increased volume there is a relative decrease in the haematocrit.

The cardiac output increases on average by approximately 35%, commencing early in the first trimester, reaching a peak at 14 to 16 weeks and remaining at a plateau until labour. In labour, cardiac output increases moderately with each contraction and more appreciably with each expulsive effort in the second stage of labour. Most of the increase in cardiac output falls dramatically very soon after delivery (Fig. 1).

The increase in cardiac output in pregnancy is the result of an increase in pulse rate and stroke volume. The heart rate increases on average by 15 to 20 beats per minute and the stroke volume by 5–10 ml. Cardiac output is also influenced by maternal position. In the supine position (the patient lying on her back), venous return is reduced owing to pressure exerted by the pregnant uterus on the inferior vena cava. This reduced return leads to reduced output and hypotension (supine hypotension syndrome). This phenomenon is most often seen in late pregnancy.

Arterial blood pressure (Fig. 2)

In the lateral recumbent position, the blood pressure is higher in the upper arm than the lower (10–12 mmHg). While sitting, the blood pressure is slightly higher than in the supine position. Peripheral vascular resistance decreases during pregnancy due to the relaxing effect of progesterone on the smooth muscles. The subsequent decrease in blood pressure reaches a nadir in the second trimester compared with the early third trimester – the well-known drop in blood pressure.

The average decrease in systolic blood pressure is 5–10 mmHg and the decrease in diastolic is 10–15 mmHg. If this decrease fails to occur, it is reported that such women are more likely to develop hypertension in the third trimester of pregnancy.

Definition of hypertension in pregnancy

Hypertension in pregnancy is defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg (Korotkoff 5). It should be noted that because elevations of both systolic and diastolic blood pressure have been associated with adverse maternal and foetal outcomes, both are important. Also, detecting a rise in blood pressure from ‘booking’ or pre-concep-

### Table 1. Antihypertensive Drugs for Use During Pregnancy

| Drug            | Route | Dose                | Time     | Action                          | Side effects                                    |
|-----------------|-------|---------------------|----------|---------------------------------|------------------------------------------------|
| Methyldopa      | po    | 0.25–1.5 g twice/day| 3–5 days | False neurotransmitter          | Orthostasis, sleepiness, depression              |
| Labetalol       | po    | 200–1200 mg/d two or three times/day in divided doses | 2–4 h    | Non-selective β-blockade        | Tremulousness, headache                         |
|                 | iv    | 20–40 mg iv every 30 min as needed | 5 min    |                                 |                                                 |
| Nifedipine      | po    | 30–120 mg/day       | 30 min   | Calcium channel blocker         | Oedema, orthostasis, dizziness                  |
| Monohydralazine | po    | 50–300 mg/d two or three times/day | 1–2 h    | Direct vasodilator              | Lupus-like syndrome with chronic use            |
|                 | iv    | 10 mg every 2 h as needed | 20–30 min|                                 |                                                 |
| Dihydralazine   | po    | 12.5–25 mg daily    | 3–5 d    | Diuretic                        |                                                 |
| Hydrochlorothiazide | po | 12.5–25 mg daily | 3–5 d    |                                 |                                                 |
| Emergency Medications |   |                     |          |                                 |                                                 |
| Labetalol as noted | po |                     |          |                                 |                                                 |
| Hydralazine as noted | iv |                     |          |                                 |                                                 |
| Nifedipine as noted | po |                     |          |                                 |                                                 |
| Diazoxide       | iv    | 30–50 mg every 5–15 min | 2–4 min  | Direct vasodilator              | Hypotension, hypoglycaemia                       |
| Nitroprusside   | iv    | 0.25 μg/kg/min      | 1–2 min  | Direct vasodilator              | Hypotension, cyanide toxicity if used > 4 h     |

**po = per os; iv = intravenous**
tion blood pressure (> 30/15 mmHg) should lead to closer monitoring, but it is not diagnostic of hypertension in pregnancy.12

**Chronic hypertension**

Chronic hypertension presents prior to pregnancy or before the twentieth week of gestation. It is reported to complicate 3% of all pregnancies and is more common in women who are obese or those over the age of 35 years. It is important to note that 20–30% of women with chronic hypertension go on to develop superimposed pre-eclampsia.13

**Pre-eclampsia/eclampsia syndrome**

Pre-eclampsia is a syndrome of new-onset hypertension (> 140/90 mmHg) occurring after the twentieth week of gestation, with proteinuria (2+ on dipstick on two occasions six hours apart or > 3 g/24-hour urine collection).13

The aetiology remains elusive but current views suggest that it is a two-stage disorder.14 Put simply, the first stage is one of placental hyperperfusion, resulting in the release of a variety of substances (apoptotic cells, trophoblastic debris and anti-angiogenic factors) which cause multisystemic endothelial damage. The second stage presents as the clinical syndrome of hypertension, proteinuria, hepatic and central nervous system dysfunction.14 It is difficult to predict which organ system will be predominantly affected, but in general terms, the clinical signs of hypertension and proteinuria are the commonest. Pre-eclampsia therefore represents a spectrum of endothelial damage leading to downstream health effects.

Pre-eclampsia is divided into mild and severe categories. Severe disease is characterised by hypertension, namely, blood pressure values above 160/100 mmHg, proteinuria above 5 g per 24 hours, neurological symptoms (headache, visual disturbances), renal compromise (elevated serum creatinine and urea), hepatic dysfunction and haemyolysis, and intra-uterine growth restriction. The presence of these symptoms and signs constitutes a medical/obstetric emergency, requiring admission to hospital and a multi-disciplinary approach to management.12

Although the exact aetiological mechanism is not known, epidemiological evidence suggests that pre-eclampsia affects the future health of the woman and her baby. Women with a history of pre-eclampsia are twice as likely to develop hypertension and/or those over the age of 35 years. It is important to note that 20–30% of women with chronic hypertension go on to develop superimposed pre-eclampsia.13

**Antihypertensive drugs in pregnancy**

Table 1 lists the commonly used antihypertensive drugs. First-line agents include methyldopa, nifedipine and labetalol. Methyldopa is the most commonly used antihypertensive medication and the most studied. It has a long history of safety, is well tolerated and efficacious, and is often the first medication attempted in pregnant women. Methyldopa can be used three times daily, particularly if high doses are required. This dose makes it a cost-effective method of treatment. Labetalol has also been studied extensively and found to be effective, although some studies have associated it with foetal growth restriction.

Angiotensin converting enzymes/angiotensin receptor blockers should be avoided in pregnancy and in women intending to become pregnant. These agents are associated with renal agensis and foetal death.15 If a woman becomes pregnant while on angiotensin converting enzymes/angiotensin receptor blockers, these agents should be stopped immediately and alternate agents that have been found to be safe in pregnancy should be used. It is also important to note that if these agents are to be considered for use in young women of childbearing age, careful counselling and contraceptive advice must be offered.12,20

There are theoretical concerns regarding the use of diuretics during pregnancy. These include decreased placental perfusion and neonatal thrombocytopenia; therefore diuretics are not first-line agents. Calcium channel blockers are used in pregnancy. Most of the literature is on the use of nifedipine and it is regarded as safe for use in pregnancy. Other calcium channel blockers are probably safe although the manufacturers do not recommend their use. Selective β-blockers are considered safe during pregnancy but high doses are associated with neonatal hypoglycaemia and low birth-weight babies.16

Antihypertensive medication needs to be continued after delivery because blood pressure remains elevated for at least three to five days following delivery. Observational studies suggest that up to 25% of women with severe pre-eclampsia have ongoing postnatal hypertension.5 Consequently, a step-down approach to reducing the use of antihypertensive agents should be taken rather than stopping abruptly. Most antihypertensive agents are expressed in breast milk in minimal quantities.

**Hypertension in young women: pregnancy and the general practitioner**

In South Africa, the general practitioner is often faced with
women requesting a diagnostic test for pregnancy. It is incumbent on these professionals to ensure that blood pressure measurements are taken, so that careful counselling is given about the options of antihypertensive agents in respect of their safety in pregnancy. General practitioners also need to be aware of the supine hypotensive syndrome associated with pregnancy and the fact that Korotkoff 5 is used for measurement of diastolic blood pressure in pregnancy.23

Furthermore, general practitioners may be faced with a pregnant women presenting with severe hypertension during pregnancy, with or without symptoms and signs of a hypertensive emergency. These situations must be recognised and antihypertensive therapy initiated prior to referral to an appropriate health facility or specialist.

Figs 3 and 4 summarise clinical management and may be useful for general practitioners, obstetricians and physicians. Ideally, such patients should be managed in referral centres, staffed by experts in hypertensive disorders of pregnancy.

Conclusions

Hypertension in pregnancy is associated with significant maternal and perinatal morbidity and mortality. Regular blood pressure monitoring, detection of signs of pregnancy-associated hypertensive therapy initiated prior to referral to an appropriate health facility or specialist.

Fig. 3. Management of mild gestational hypertension or pre-eclampsia.

Fig. 4. Management of severe pre-eclampsia.

hypertensive conditions and management by health professionals experienced in this field will minimise sequelaes associated with hypertensive disorders in pregnancy, and may have a positive impact on women’s cardiovascular events and outcomes years after the affected pregnancies.

References

1. Report on the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: 51–522.
2. Panday M, Mantel GD, Moodley J. Audit of severe acute morbidity in hypertensive pregnancies in a developing country. J Obstet Gynaecol 2004; 24(4): 387–391.
3. Moodley J, Kalane G. A review of the management of eclampsia: practical issues. J Hypertens Pregnancy 2006; 25: 47–62.
4. Harshkaqmp RE, Zeeman GG. Pre-eclampsia: at risk for remote cardiovascular disease. Am J Med Sci 2007; 334: 291–295.
5. Wilson BJ, Watson MS, Prescott GI, Sunderland S, Campbell DM, Hannaford P, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. Br Med J 2003; 326: 845–851.
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. and the National High Blood Pressure Education Program Co-ordinating committee. The 7th Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure : the JNC 7 Report. J Am Med Assoc 2003; 289: 2560–2572.
7. Gavard JA, Artal R. Effect of exercise on pregnancy outcome. Clin Obstet Gynecol 2008; 51: 467–480.
8. Sorensen TK, Williams MA, Lee IM, Dashow EE, Thompson ML, Luthy DA. Recreational physical activity during pregnancy and risk of pre-eclampsia. Hypertension 2003; 41: 1273–1280.
9. Saftlas AF, Logsdon-Sackett N, Wang W, Woolson R, Bracken MB. Work, leisure-time physical activity, and risk of pre-eclampsia and gestational hypertension. Am J Epidemiol 2004; 160: 758–765.
10. Rudra CB, Sorensen TK, Luthy DA, Williams MA, Luthy DA. A prospective analysis of recreational physical activity and pre-eclampsia risk. Med Sci Sports Exerc 2008; 40: 1836–1841.
11. Kruger TF, de Bruijn JM. Physiological adaptations in pregnancy. In: Obstetrics in Southern Africa. Cronje HS, Grobler CJF, eds. Pretoria: Van Schaik Publishers, 2008: 15–22.
12. Lowe SA, Brown MA, Dekker GA, et al. Guidelines for the management of hypertensive disorders of pregnancy. A NZ J Obstet Gynaecol 2008; 42: 242–246.
13. Yoder SR, Thorburg MD, Bisognano JD. Hypertension in pregnancy and women of childbearing age. Am Med J 2009; 122: 890–895.
14. Roberts JM, Rajakumar a. pre-eclampsia and soluble fms-like tyrosine kinasel. J Clin Endocrinol Metab 2009; 94(7): 2252–2254.
15. Moodley J. Hypertensive emergencies in pregnancy in under-resourced countries. Curr Opin Obstet Gynecol 2008; 20(2): 91–95.
16. Panday M, Moodley J. Management of the unconscious pregnant patient. Best Prac Res Clin Obstet Gynaecol 2009; 23: 327–328.
17. Parak F, Moodley J. Untoward effects of rapid-acting antihypertensive agents. Best Prac Res Clin Obstet Gynaecol 2001; 15(4): 491–506.
18. Magee LA. Antihypertensives. Best Prac Res Clin Obstet Gynaecol 2001; 15(6): 827–845.
19. Martin Jr, Thiessen BD, Brad D, et al. Stroke a pre-eclampsia and eclampsia: a paradigm shift focussing on systolic blood pressure. Obstet Gynecol 2005; 105(2): 246–254.
20. Briggs GG, Freeman RF, Yaffe SJ. Drugs in Pregnancy and Lactation: a Reference Guide to Fetal and Neonatal Risk. 8th edn. Baltimore: Lippincourt Williams and Wilkins, 2008.
21. Smith P, Anthony J, Johanson R. Nifedipine in pregnancy. Br J Obstet Gynaecol 2000; 107: 299–307.
22. Broughton-Pipkin F, Roberts JM. Hypertension in pregnancy. J Hum Hypertens 2000; 14(10-11): 705–724.
23. Roberts JM, Hubel CA. The two stage model of pre-eclampsia: variations on the theme. Placenta 30 suppl A. Trophoblast Res 2009; 23: S32–S37.

Cardiovascular Journal of Africa 2010 winner of best scientific article

The first Andries Brink Kaye award for the most outstanding article published in 2010 in the Cardiovascular Journal of Africa was awarded during the South African Heart Congress in East London.

Prof Andries Brink, left, with award winner Andrea de Kock, for her article titled “Coping and metabolic syndrome indicators in urban black South African men: the SABPA study.”

Photograph kindly supplied by SA Cardiology & Stroke Journal